Date published July 2010

 

Print copies are available upon request. Call 781-972-5444. 

For Corporate Subscriptions, Multi-Reports Orders, Discounts or Order Questions.  

Contact:
Kerri Kelley
Customer Service
781-972-1347 


IPR Bundle

Therapeutic Protein Production: A Changing Landscape Report - Tables and Figures

 

Author: K. John Morrow, Jr. Ph.D.

TABLES
Table 1.1. A Wide Range of Species Under Study for Protein Production 
Table 2.1. Selected List of Approved Recombinant Therapeutic Proteins Produced in Mammalian Cell Lines (Messi 2009, See Appendix) 
Table 2.2. Mammalian Cell Culture Products and Media 
Table 2.3. Recommendations by Regulatory Agencies and Physicians‘ Organizations for the Avoidance of Human or Animal Proteins in Drug Manufacturing 
Table 2.4. Approved Therapeutic Protein-Based Products from E. coli. 
Table 2.5. Comparison of Plants Built to Accommodate Reusable Versus Disposable Upstream Bioprocessing Facilities 
Table 3.1. Various Polishing Options 
Table 3.2. Typical Platform for MAb Purification 
Table 3.3. Companies Dealing with Liquid Chromatography Systems and Products  
Table 4.1. FDA Biologics Approvals, 2009 
Table 6.1. Comparative Salaries (in US $$) for High-Tech Occupations in Various Countries, 2008 

FIGURES
Figure 2.1. Number (and Percentage Values Siding the Bars) of Recombinant Proteins Approved as Biopharmaceuticals in Different Production Systems* 
Figure 2.2. General Scheme for Commercial Development and Production of a Plasma-Free Recombinant Therapeutic Protein. In Every Step of the Manufacturing Process, Animal- or Human-Derived Additives Are Replaced by Plant-Based or Synthetic Moleculesa). 
Figure 6.1. Cell-Free Synthesis Production Example